Cytomx Therapeutics Stock Today
| CTMX Stock | USD 0.87 0.02 2.25% |
Performance0 of 100
| Odds Of DistressOver 60
|
CytomX Therapeutics is trading at 0.87 as of the 21st of November 2024; that is 2.25 percent decrease since the beginning of the trading day. The stock's open price was 0.89. CytomX Therapeutics has more than 60 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. Equity ratings for CytomX Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 22nd of October 2024 and ending today, the 21st of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 8th of October 2015 | Category Healthcare | Classification Health Care |
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California. Cytomx Thera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 78.26 M outstanding shares of which 5.67 M shares are currently shorted by private and institutional investors with about 9.58 trading days to cover. More on CytomX Therapeutics
Moving together with CytomX Stock
Moving against CytomX Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
CytomX Stock Highlights
| Chairman CEO | Sean DPHIL | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Cancer Fighters (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCytomX Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand CytomX Therapeutics' financial leverage. It provides some insight into what part of CytomX Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CytomX Therapeutics (CTMX) is traded on NASDAQ Exchange in USA. It is located in 151 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 and employs 120 people. CytomX Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 68.09 M. CytomX Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 78.26 M outstanding shares of which 5.67 M shares are currently shorted by private and institutional investors with about 9.58 trading days to cover.
CytomX Therapeutics currently holds about 194.29 M in cash with (56.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check CytomX Therapeutics Probability Of Bankruptcy
Ownership AllocationCytomX Therapeutics holds a total of 78.26 Million outstanding shares. Over half of CytomX Therapeutics' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check CytomX Ownership Details
CytomX Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Rtw Investments, Llc | 2024-06-30 | 1.2 M | |
| Superstring Capital Management Lp | 2024-06-30 | 1.2 M | |
| Blackrock Inc | 2024-06-30 | 1.1 M | |
| Renaissance Technologies Corp | 2024-09-30 | 1 M | |
| Geode Capital Management, Llc | 2024-06-30 | 769.5 K | |
| Two Sigma Investments Llc | 2024-06-30 | 661.9 K | |
| Adar1 Capital Management Llc | 2024-06-30 | 572.2 K | |
| Citadel Advisors Llc | 2024-06-30 | 494.6 K | |
| Sei Investments Co | 2024-06-30 | 382.7 K | |
| Tang Capital Management Llc | 2024-06-30 | 7.8 M | |
| Hhg Plc | 2024-06-30 | 6.3 M |
CytomX Therapeutics Historical Income Statement
CytomX Stock Against Markets
CytomX Therapeutics Corporate Management
| JD Rowland | General VP | Profile | |
| MBA BS | Head VP | Profile | |
| Danielle OlanderMoghadassian | Senior Officer | Profile | |
| YuWaye MD | Senior Officer | Profile | |
| Christopher Ogden | Principal Accounting | Profile |
Additional Tools for CytomX Stock Analysis
When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.